In case of RT, all patients should be treated by IMRT or VMAT [I, A]. 3d. The treatment strategy for HPV-positive SCCHN should be the same as Nivolumab is both FDA- and EMA-approved for recurrent/metastatic patients who progress within 6 months of platinum therapy [I, A; ESMO-MCBS....